Health GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune Risk Posted on March 5, 2024 by miyuru TOPLINE: In clients with type 2 diabetesthere was no distinction in threat of establishing autoimmune illness if recommended glucagon-like peptide 1 receptor agonists (GLP-1-RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl….